10-Q: IR-Med Faces Going Concern Doubt Amid Rising Losses

IR-Med, Inc. reported increased losses and significant cash flow challenges, raising substantial doubt about its ability to continue as a going concern.

Summary

• Reported a net loss of $1,474 thousand for the six months ended June 30, 2025, an increase from $1,023 thousand in the prior year period.
• Cash and cash equivalents decreased to $63 thousand as of June 30, 2025, from $129 thousand at December 31, 2024.
• Accumulated deficit reached $18,212 thousand as of June 30, 2025.
• Management believes current cash resources will only be sufficient through August 2025, indicating a going concern risk.
• The company is developing PressureSafe, a device for early assessment of pressure injuries, with initial pilots planned for Q4 2025.
• DiaSafe, a device for diabetic foot ulcer assessment, is under development and received an advance payment of $171,468 from the Israeli Innovation Authority (IIA).
• A significant financial expense of $935 thousand was recorded for the six months ended June 30, 2025, primarily due to non-cash expenses related to an equity purchase agreement.
• Williamsburg Venture Holdings, LLC failed to remit $500,000 for put shares under an Equity Purchase Agreement, leading the company to pursue legal means.
• Cost-cutting measures were implemented, including salary reductions for officers and termination of the Chief Development Officer's employment.

Sentiment

Score: 2

Explanation: The company faces severe financial distress, evidenced by increasing losses, critically low cash reserves, and a going concern warning. The failure of a significant financing agreement and ongoing legal proceedings add substantial risk, overshadowing operational progress in product development and cost-cutting measures.

Positives

• Net cash used in operating activities decreased to $181 thousand for the six months ended June 30, 2025, from $730 thousand in the prior year, reflecting cost-cutting measures.
• Research and development expenses, net, decreased to $114 thousand for the six months ended June 30, 2025, from $289 thousand in the prior year, partly due to completion of PressureSafe development.
• Marketing expenses significantly decreased to $3 thousand for the six months ended June 30, 2025, from $196 thousand in the prior year.
• General and administrative expenses decreased to $422 thousand for the six months ended June 30, 2025, from $531 thousand in the prior year.
• Received an advance payment of approximately $171,468 from the Israeli Innovation Authority (IIA) for the development of the DiaSafe device, part of a larger grant of approximately $489,035.
• PressureSafe device received U.S. FDA listing certification on April 9, 2024, and initial pilots are planned for Q4 2025.

Negatives

• Net loss increased to $1,474 thousand for the six months ended June 30, 2025, from $1,023 thousand in the prior year.
• Cash and cash equivalents declined to $63 thousand as of June 30, 2025, from $129 thousand at December 31, 2024.
• Accumulated deficit grew to $18,212 thousand as of June 30, 2025.
• Total liabilities increased to $800 thousand as of June 30, 2025, from $545 thousand at December 31, 2024.
• Stockholders deficit worsened to $(625) thousand as of June 30, 2025, from $(294) thousand at December 31, 2024.
• Financial expenses, net, surged to $935 thousand for the six months ended June 30, 2025, from $7 thousand in the prior year, primarily due to non-cash expenses from an equity purchase agreement.
• Williamsburg Venture Holdings, LLC failed to remit $500,000 for put shares, forcing the company to pursue legal action.
• The company's cash resources are only sufficient to meet operating and capital needs through August 2025, raising substantial doubt about its ability to continue as a going concern.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to recurring losses, negative cash flows, and insufficient cash resources beyond August 2025.
• Failure to obtain additional financing could force the company to delay, reduce, or eliminate development programs, materially adversely affecting its business.
• The ongoing lawsuit seeking approximately $2.3 million in damages could result in significant financial liability if the company is unsuccessful in its defense.
• Regional instability and potential escalation of the Iron Swords War could negatively impact global and regional conditions, adversely affecting the company's business and financing efforts.
• Reliance on third-party manufacturers and the ability to transition from pilot-scale to large-scale manufacturing pose operational risks.
• The company is subject to risks common in the medical device industry, including the need for marketing approval, reimbursement, successful commercialization, dependence on key personnel, and protection of proprietary technology.
• Changes in U.S. laws or policies, including trade policies and tariffs, could increase manufacturing costs and disrupt the supply chain.

Future Outlook

The company plans to continue development efforts for its products, mainly focusing on the DiaSafe device, and the production and marketing of PressureSafe commercial units. Initial pilots for PressureSafe are planned for the last quarter of 2025. The company expects to incur additional costs and will require significant additional capital to fund operations, intensify R&D, strengthen its patent portfolio, establish operations, and pursue regulatory approvals. Management is actively seeking additional financing arrangements.

Management Comments

• "Managements plans regarding these matters include continued development and marketing the Companys products, as well as seeking additional financing arrangements."
• "Although management continues to pursue these plans, in the event financing is not obtained, the Company may pursue additional cost cutting measures or may be required to delay, reduce the scope of, or eliminate any of its development programs, these events could have a material adverse effect on its business."
• "The Company will continue to seek payment for the put shares from Williamsburg and intends to pursue any legal means available to it to enforce the terms of the Agreement."
• "We expect that our existing cash and cash equivalents will enable us to fund our operations and capital expenditure requirements through the third quarter of 2025."
• "We are planning to raise additional capital to continue our operations, as well as to explore additional avenues to increase revenues and reduce expenditures."

Industry Context

IR-Med operates in the highly competitive and capital-intensive medical device industry, specifically focusing on non-invasive diagnostic tools using infrared spectroscopy and AI. The market for early assessment of pressure injuries and diabetic foot ulcers is substantial, driven by the need to reduce healthcare costs and improve patient outcomes. The company's technology aims to address misdiagnosis, a common issue in diagnostics. However, as a pre-revenue company, it faces significant challenges in securing funding, navigating regulatory approvals, and establishing market presence against larger, more established players. The FDA listing for PressureSafe is a positive step, but commercialization and market adoption remain critical hurdles.

Comparison to Industry Standards

• As a pre-revenue company, direct comparisons to established industry leaders like Medtronic, Johnson & Johnson, or Abbott Laboratories in terms of revenue or profitability are not applicable.
• The company's focus on AI-powered non-invasive diagnostics aligns with broader industry trends towards advanced, less intrusive medical technologies, similar to innovations seen in companies like AliveCor (ECG devices) or various digital health startups.
• The FDA Class I listing for PressureSafe is a standard regulatory milestone for low-risk devices, but achieving widespread adoption and reimbursement will require significant commercialization efforts, comparable to other new entrants in the medical device space.
• The substantial accumulated deficit and going concern warning are common for early-stage biotech/medtech companies but indicate a critical need for successful product launch and significant capital infusion, which is a higher risk profile compared to mature industry players.

Management Changes

Corporate Governance

Legal Proceedings

• A lawsuit filed on May 29, 2023, against the company, its subsidiary, and a director for alleged breach of contract and non-payment for consulting services, seeking approximately $2.3 million in damages. Mediation failed, and an additional pre-trial hearing is scheduled for September 15, 2025. No provision has been made as management believes the allegations are baseless.

Related Party Transactions

• Two officers agreed to reduce their salaries for January and February 2025, and again from June 2025, due to the company's cash position.
• The Chief Financial Officer's employment agreement was amended on July 23, 2025, reducing his monthly salary and benefits, and decreasing his scope of employment to 25% starting August 1, 2025.
• The Chief Development Officer's employment was terminated on August 3, 2025, with the intent to retain his services on a consultancy basis.
• Convertible promissory notes for an aggregate amount of $31,200 were issued to Mr. Ran Ziskind (CEO), Mr. Yaniv Cohen, and Mr. Oded Bashan (related parties).

Stakeholder Impact

• **Shareholders:** Face significant dilution risk from potential future capital raises and existing stock-based compensation. The going concern warning and failure of a major financing agreement pose substantial risk to investment value. The increase in accumulated deficit further erodes shareholder equity.
• **Employees:** Experienced salary reductions and employment termination (Chief Development Officer), indicating cost-cutting measures due to financial constraints. Future employment stability may be uncertain given the going concern risk.
• **Creditors:** The increase in total liabilities and the going concern warning suggest elevated risk for creditors, although some loans have had repayment dates extended.
• **Customers/Patients:** Potential delays or reductions in product development programs due to financing issues could impact the availability of PressureSafe and DiaSafe devices, affecting future patient care.

Next Steps

• Continue usability studies and preparations for the commercial launch of PressureSafe.
• Initiate initial pilots for the PressureSafe device in Q4 2025.
• Continue development of the DiaSafe device, funded by the IIA grant.
• Pursue legal means to enforce the Equity Purchase Agreement against Williamsburg Venture Holdings, LLC for the unremitted $500,000.
• Attend an additional pre-trial hearing for the $2.3 million lawsuit scheduled for September 15, 2025.
• Seek additional financing arrangements to address the going concern risk and fund future operations and development programs.
• Retain the Chief Development Officer on a consultancy basis following employment termination.

Key Dates

Recommendation

The company faces severe financial distress, highlighted by a substantial going concern warning, critically low cash reserves ($63,000), and an accumulated deficit of over $18 million. The significant increase in net loss, primarily driven by non-cash financial expenses related to a failed equity purchase agreement, underscores operational and financial instability. The failure of Williamsburg Venture Holdings to remit $500,000 for put shares is a major setback, indicating difficulty in securing crucial funding. While cost-cutting measures and progress in product development (FDA listing for PressureSafe, IIA grant for DiaSafe) are noted, they are insufficient to offset the immediate and existential financial risks. The company's cash is projected to last only through August 2025, necessitating urgent and uncertain capital raises. Given these factors, the stock carries an extremely high risk profile with a high probability of further value erosion or potential insolvency.

Keywords

Medical Device, Infrared Spectroscopy, Artificial Intelligence, PressureSafe, DiaSafe, Diabetic Foot Ulcer, Pressure Injuries, FDA Listing, Going Concern, Capital Raise, SEC Filing, Biomarkers, Non-invasive Diagnostics